Biologics Market

According to IMARC Group latest report titled “Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on biologics market. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global biologics market size reached US$ 321.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 535.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.

Biologics, a cornerstone of modern therapeutic practices, are complex medicines made from living organisms. These advanced pharmaceuticals are manufactured using biotechnology, involving the use of living cells and organisms to produce therapeutic substances. Unlike conventional drugs synthesized chemically, biologics are derived from a variety of natural sources, including humans, animals, and microorganisms. The spectrum of biologics includes a diverse range of products, such as monoclonal antibodies, vaccines, recombinant proteins, gene therapies, and cell therapies.

Each type serves unique therapeutic purposes, targeting specific cells and pathways within the body. The advantages of biologics lie in their ability to treat and manage a wide array of medical conditions, particularly those that were previously untreatable with conventional medicines. They offer precision in targeting specific components of the body's immune system and disease processes, leading to higher efficacy and often fewer side effects compared to traditional drugs. This precision in treatment has made biologics a critical element in the management of chronic diseases, rare genetic disorders, and various forms of cancer.

Get a Sample Copy of this Report: https://www.imarcgroup.com/biologics-market/requestsample

Market Trends:

The global biologics market is witnessing exponential growth, driven by the advancement of healthcare and medicine. Additionally, the increasing prevalence of chronic diseases and complex medical conditions, which require more sophisticated and targeted therapeutic approaches, is positively influencing the market. Biologics, with their high specificity and effectiveness, are becoming the treatment of choice for conditions such as rheumatoid arthritis, psoriasis, and various types of cancer. This growing demand is influencing continuous research and development in the field, leading to the introduction of novel biologics with improved efficacy and safety profiles. Therefore, this is significantly supporting the market. Along with this, advancements in biotechnology and genetic engineering are also playing a significant role in market growth. These technological breakthroughs are enabling the development of more advanced biologics that can be tailored to individual patient needs, enhancing treatment outcomes. In addition, the increasing focus on personalized medicine is further providing a boost to the adoption of biologics in therapeutic regimens. Another significant trend is the rising investment in healthcare infrastructure and research by governments and private entities worldwide. This investment is facilitating the development and accessibility of biologics, especially in emerging economies.

Moreover, regulatory support for biologics, including faster approvals and patent protections, is encouraging pharmaceutical companies to invest in biologic drug development. Apart from this, the aging global population, which is more susceptible to chronic diseases, is also contributing to the growth of the market. As life expectancy increases, the demand for advanced treatments that can improve quality of life and manage age-related health issues is accelerating. Furthermore, the growing awareness and acceptance of biologics among patients and healthcare professionals are creating a positive market outlook. Some of the other factors driving the market include rapid industrialization and technological advancements.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• AbbVie Inc.

• Amgen Inc.

• AstraZeneca plc

• Hoffmann-La Roche Ltd

• GlaxoSmithKline plc

• Johnson & Johnson

• Merck KGaA

• Novartis AG

• Pfizer Inc.

• Sanofi

Biologics Market Segmentation:

Our report has categorized the market based on region, source, product, disease and manufacturing.

Breakup by Source:

• Microbial

• Mammalian

• Others

Breakup by Product:

• Monoclonal Antibodies

• Vaccines

• Recombinant Proteins

• Antisense, RNAi and Molecular Therapy

• Others

Breakup by Disease:

• Oncology

• Immunological Disorders

• Cardiovascular Disorders

• Hematological Disorders

• Others

 Breakup by Manufacturing:

• Outsourced

• In-House

Breakup by Region:

• North America (United States, Canada)

• Europe (Germany, France, United Kingdom, Italy, Spain, Others)

• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

• Market Performance (2017-2022)

• Market Outlook (2023-2028)

• Porter’s Five Forces Analysis

• Market Drivers and Success Factors

• SWOT Analysis

• Value Chain

• Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800